Company Research
ATOS US
ATOS Stock Jumped: FDA Orphan Drug Designation for (Z)-Endoxifen Explained
What the FDA’s ODD signal can mean, what it doesn’t mean, and how to verify the catalyst in filings fast
Michael Chen
Michael Chen is a senior financial analyst and investment researcher with over 15 years of experience covering global equity markets. He specializes in technology sector analysis, fundamental valuation, and macroeconomic trends affecting institutional portfolios.
Equity ResearchFinancial ModelingSEC Filings AnalysisTechnology StocksMacroeconomic AnalysisValuation MethodsEarnings AnalysisRisk AssessmentPortfolio ManagementESG Investing
219 published articles • Page 12
Articles by Michael Chen
Company Research
NVO US
Wegovy 7.2 mg Dose Approval: What It Means for Novo Nordisk (NVO)
MHRA’s updated Wegovy dosing guidance, who it applies to, and an investor checklist to track what changes next
Equity Research
RDDT US
Reddit Stock Drops 9%: Retail Sentiment, Ad Weakness, and What to Watch Next (RDDT)
A practical, filing-first checklist to assess advertising risk, insider selling signals, and the next catalyst—using Alpha Analyst.
Company Research
BMNR US
BitMine (BMNR) Authorized Shares Increase: What the 50 Billion Vote Means
A practical investor guide to reading the proxy, separating signal from hype, and tracking dilution risk in Alpha Analyst
